R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Big promises, hard work: What 2026 will demand from pharma

Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.

R&D

Clinical research demands agile CROs

An emerging consensus across sponsors, investigators, and regulators is that agility must become a defining attribute of CRO performance.

R&D

Europe has the tools to fight superbugs. Let’s use them.

Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help.

R&D

Black mouse in a lab on scientist's hand

FDA’s emerging framework to reduce animal testing: Implicati...

Exploring the strategic shift toward reducing reliance on non-human primates (NHPs) and other animal species in R&D.

R&D

Bringing therapies to patients quicker with integrated CDMO ...

Biotechs and pharmaceutical companies can receive enormous value from a trusted partnership with an integrated CDMO and CRO.

R&D

Unlocking the future of obesity treatment

Obesity is more than a number on the scale, it’s a complex, malignant disease linked to diabetes, cardiovascular conditions, and even certain cancers.